Health Discovery Corporation (OTCBB: HDVY) today announced its agreement with the U.S. Preventive Services Task Force’s (USPSTF) stance against the use of the prostate-specific antigen (PSA), a test used by 90 percent of U.S. men to screen for prostate cancer. In a draft recommendation released Friday, the Task Force sided against the PSA test, stating that patients are substantially more likely to be harmed by the adverse effects of aggressive treatment prompted by ambiguous test results than they are to reap benefits such as better health or longer life. HDC agrees with reported results that a patient’s quality of life may suffer from overtreatment caused by anxiety, urinary incontinence, erectile dysfunction, impotence, coronary heart decease, diabetes, increased breast size and hot flashes, depending on treatment. HDC adds that diminished reliance on PSA testing will also help reduce cases of infection and/or nerve damage that have been reported by some patients following biopsy procedures. However, HDC supports prostate cancer screening with a more reliable prostate cancer test and believes that such screening will save lives.

"In a recent clinical trial, HDC’s urine based four-gene prostate cancer test successfully outperformed serum PSA," stated Dr. Herbert Fritsche, Chief Science Officer, Health Discovery Corporation and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. "The HDC urine-based four gene prostate cancer test was shown to identify 90% of cancers while eliminating 50% of unnecessary biopsies and therefore significantly reducing potentially unnecessary treatments including surgeries that would otherwise have been performed."

Further explaining the advanced development of HDC’s urine-based prostate cancer test, Stephen D. Barnhill, M.D., Chairman and CEO, Health Discovery Corporation, notes that, "We have now demonstrated to our satisfaction that the 4-gene urine test for clinically significant prostate cancer outperformed serum PSA and Digital Rectal Exam (DRE), as well as published data for PCA3 and TMPRSS-ERG assays for the early detection of prostate cancer.” Furthermore, additional studies are planned to explore the potential of the 4-gene test to distinguish patients with aggressive disease that require aggressive therapy from those who have a more benign cancer and do not need aggressive treatment.